Wall Street brokerages expect that Abeona Therapeutics Inc. (NASDAQ:ABEO) will report sales of $230,000.00 for the current quarter, Zacks reports. Two analysts have made estimates for Abeona Therapeutics’ earnings, with the highest sales estimate coming in at $250,000.00 and the lowest estimate coming in at $200,000.00. Abeona Therapeutics reported sales of $180,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 27.8%. The company is expected to report its next earnings results on Monday, November 13th.

On average, analysts expect that Abeona Therapeutics will report full year sales of $230,000.00 for the current year, with estimates ranging from $800,000.00 to $930,000.00. For the next financial year, analysts forecast that the company will report sales of $1.26 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.21 million.

ABEO has been the topic of a number of recent research reports. Maxim Group set a $14.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 25th. FBR & Co restated a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, May 26th. Jefferies Group LLC restated a “buy” rating and issued a $11.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, June 1st. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, June 6th. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.50.

Abeona Therapeutics (NASDAQ ABEO) opened at 16.50 on Tuesday. The firm has a 50-day moving average of $10.50 and a 200-day moving average of $7.13. Abeona Therapeutics has a 1-year low of $4.05 and a 1-year high of $17.90. The stock’s market cap is $664.74 million.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after purchasing an additional 108,730 shares during the last quarter. Highbridge Capital Management LLC raised its stake in Abeona Therapeutics by 23.5% in the 1st quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock valued at $3,408,000 after purchasing an additional 129,811 shares during the last quarter. State Street Corp acquired a new position in Abeona Therapeutics in the 2nd quarter valued at $1,900,000. Northern Trust Corp raised its stake in Abeona Therapeutics by 406.3% in the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 206,775 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in Abeona Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 204,590 shares of the biopharmaceutical company’s stock valued at $1,023,000 after purchasing an additional 30,300 shares during the last quarter. 38.24% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Abeona Therapeutics Inc. (ABEO) Will Post Quarterly Sales of $230,000.00” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/19/analysts-expect-abeona-therapeutics-inc-abeo-will-post-quarterly-sales-of-230000-00.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.